First Opinion By Jeremy Schafer Should employers take a chance on little-known Embarc to pay for gene therapy?
Pharma By Adam Feuerstein At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug
Biotech By Eric Boodman ‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price
First Opinion By Fred D. Ledley 30 years is too long to wait for new medicines. There are ways to speed up drug development
In the Lab By Sharon Begley Gene therapy for sickle cell moves closer as scientists clear unexpected obstacle
Health By Elizabeth Cooney Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future
In the Lab By Rebecca Robbins Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
Pharmalot By Ed Silverman Novartis unit says FDA wasn’t told of data manipulation sooner because it was ‘highly complex’
Biotech By Jonathan Saltzman — Boston Globe The world’s most expensive medicine could save toddlers’ lives. But getting it is complicated
Biotech By Adam Feuerstein Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate
Biotech By Adam Feuerstein and Matthew Herper Biomarin to seek approval for hemophilia gene therapy, but durability questions persist
Biotech By Jonathan Saltzman — Boston Globe Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy
Biotech By Adam Feuerstein Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst
Biotech By Adam Feuerstein BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know
Biotech By Adam Feuerstein With positive early results, Sarepta appears to have a second gene therapy with potential
Biotech By Matthew Herper Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint
Biotech By Adam Feuerstein With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease
Adam's Take By Adam Feuerstein Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy
Biotech By Adam Feuerstein Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders
Adam's Take By Adam Feuerstein A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology
Biotech By Ike Swetlitz FDA plans to speed path to approval for some gene therapies, starting with hemophilia
Pharmalot By Ed Silverman Pharmalittle: Insulin study causes a big flap; Glaxo gets a reprieve thanks to a Novartis setback
Biotech By Adam Feuerstein FDA approves first gene therapy targeting rare form of inherited blindness
Adam's Take By Adam Feuerstein Spark Therapeutics’s success is lifting all gene therapy stocks even though risks remain
Biotech By Adam Feuerstein Spark’s novel gene therapy for blindness is racing to a historic date with the FDA